Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176974 | 0.84 | ABCB1 (0.47) | NR1H2NR1H3RXRAABCB1RORC | |
| SCHEMBL5162369 | 0.84 | ABCB1 (0.47) | NR1H2NR1H3RXRAABCB1RORC | |
| SCHEMBL5162024 | 0.84 | ABCB1 (0.47) | NR1H2NR1H3RXRAABCB1RORC | |
| SCHEMBL5159580 | 0.83 | ABCB1 (0.41) | NR1H2NR1H3RXRAABCB1RORC | |
| SCHEMBL5161749 | 0.83 | ABCB1 (0.41) | NR1H2NR1H3RXRAABCB1RORC | |
| SCHEMBL14446219 | 0.75 | ACHE (0.37) | ACHEMAPK1SMN1; SMN2 | |
| SCHEMBL25370884 | 0.74 | ALDH1A1 (0.41) | ABCB1ACHEBRD4 | |
| SCHEMBL30503937 | 0.74 | ALDH1A1 (0.41) | ABCB1ACHEBRD4 | |
| SCHEMBL38655199 | 0.73 | KDM1A (0.39) | NR1H2NR1H3RXRAACHEBRD4 | |
| SCHEMBL5415011 | 0.73 | TACR1 (0.54) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241798-B2 | NK1 antagonists | PFIZER INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1756056-A1 | AZA-BICYCLO[3.1.0]HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121085-A1 | AZA-BICYCLO`3.1.0!HEX-1-YL DERIVATIVES ACTIVE AS NK1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272800-A1 | NK1 antagonists | PFIZER INC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272800-A1 | NK1 antagonists | TACR1, TACR2, TAC3 | NR1H2 1508/4885NR1H3 1542/4885RXRA 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.